Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

IGF1 Protein (AA 49-118)

IGF1 Origine: Humain Hôte: Escherichia coli (E. coli) Recombinant >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis. FACS Active
N° du produit ABIN2667446
  • Antigène Voir toutes IGF1 Protéines
    IGF1 (Insulin-Like Growth Factor 1 (IGF1))
    Type de proteíne
    Recombinant
    Activité biologique
    Active
    Attributs du protein
    AA 49-118
    Origine
    • 23
    • 16
    • 7
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Source
    • 42
    • 15
    • 8
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Escherichia coli (E. coli)
    Application
    Flow Cytometry (FACS)
    Pureté
    >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.
    niveau d'endotoxine

    Less than 0.1 ng per μg of protein.

    Top Product
    Discover our top product IGF1 Protéine
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Commentaires

    Biological activity: The ED50 was determined by a cell proliferation assay using FDC-P1 cells is ≤ 2.0 ng/ml, corresponding to a specific activity of ≥ 5 x 105 units/mg.

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.
    Buffer
    Lyophilized, carrier-free.
    Conseil sur la manipulation
    Avoid repeated freeze/thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    Unopened vial can be stored at -20°C or -70°C.
  • Antigène
    IGF1 (Insulin-Like Growth Factor 1 (IGF1))
    Autre désignation
    IGF-I (IGF1 Produits)
    Synonymes
    IGF-I Protein, IGF1A Protein, IGFI Protein, C730016P09Rik Protein, Igf-1 Protein, Igf-I Protein, Npt2B Protein, IGF-1 Protein, IGFIA Protein, IGF-IB Protein, igf1 Protein, IGF-1L Protein, IGF-1a Protein, IGF1 Protein, igf-1 Protein, igf1-A Protein, igf1.S Protein, xigf1 Protein, insulin like growth factor 1 Protein, insulin-like growth factor 1 Protein, insulin-like growth factor I Protein, insulin like growth factor 1 L homeolog Protein, IGF1 Protein, Igf1 Protein, LOC100136741 Protein, igf1 Protein, LOC678666 Protein, igf1.L Protein, LOC104911603 Protein
    Sujet
    IGF-I (insulin-like growth factor 1), initially described in 1957, is a hormone that is important in childhood growth and also has anabolic effects in adults. It is a member of the IGF family that is comprised of three members: IGF-I, IGF-II, and insulin. IGF-I and IGF-II share approximately 50 % similarity with insulin at the amino acid level. Human IGF-I is synthesized as a 191 amino acid prepro-IGF-I, pro-IGF-I is processed to the mature, active protein, and this procedure requires glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-I. Deletion of muscle GRP94 impairs muscle and body growth by inhibiting local production of IGF proteins. Seven IGF binding proteins have been described (IGFBP-1 to -7). IGFBPs extend the half life and regulate the availability of IGF-I and IGF-II. It has been described that IGFBP3 is the main circulating binding protein for IGFs, in serum, approximately 75 % of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-I binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration. IGF-I deficiency is associated to growth hormone insensitivity syndrome (GHIS) also called Laron syndrome, liver cirrhosis, age-related cardiovascular and neurological diseases, and intrauterine growth restriction.
    Poids moléculaire
    The 70 amino acid recombinant protein has a predicted molecular mass of approximately 7.6 kDa. The predicted N-terminal amino acid is Gly.
    Pathways
    Signalisation RTK, Intracellular Steroid Hormone Receptor Signaling Pathway, Peptide Hormone Metabolism, Hormone Activity, Regulation of Intracellular Steroid Hormone Receptor Signaling, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Stem Cell Maintenance, Glycosaminoglycan Metabolic Process, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Activated T Cell Proliferation, Positive Regulation of fat Cell Differentiation
Vous êtes ici:
Support technique